Page 74 - 《中国药房》2025年10期

·药物与临床·

阿利西尤单抗联合阿托伐他汀对急性冠脉综合征患者 PCI 术后
临床疗效和安全性的影响
Δ

#
＊
郝翠君 ，王 蕊 ，马逸平，张雪萍，刘亚男，秦少强（河北北方学院附属第一医院心血管内科，河北 张家口
075000）

中图分类号 R969.4；R972 文献标志码 A 文章编号 1001-0408（2025）10-1216-05
DOI 10.6039/j.issn.1001-0408.2025.10.11

摘 要 目的 探讨阿利西尤单抗联合阿托伐他汀对急性冠脉综合征（ACS）患者接受经皮冠脉介入术（PCI）后临床疗效和安全性
的影响。方法 将2021年1月至2023年12月我院收治的207例患有ACS并接受PCI治疗者，按随机数字表法分为阿利西尤单抗
组、依折麦布组和对照组，每组69例。所有患者均在PCI术后接受常规预防血栓、降压等治疗。在此基础上，对照组患者采用阿托
伐他汀（20 mg/次，每天1次）治疗；依折麦布组患者采用依折麦布（10 mg/次，每天1次）+阿托伐他汀（20 mg/次，每天1次）治疗；阿
利西尤单抗组患者采用阿利西尤单抗（75 mg/次，每2周1次）+阿托伐他汀（20 mg/次，每天1次）治疗。3组患者均治疗8周，治疗
后再随访6个月。比较3组患者治疗前后的心功能指标、脂代谢指标水平以及随访期间的主要心血管不良事件（MACE）及其他药
物不良反应（ADR）的发生情况。结果 治疗8周后，3组患者的心功能和脂代谢指标水平均较同组治疗前显著改善（P＜0.05）；与
对照组和依折麦布组相比，阿利西尤单抗组患者的左室射血分数显著升高，左室舒张末期内径（LVEDD）显著缩短（P＜0.05）；与
对照组相比，依折麦布组患者的LVEDD显著缩短（P＜0.05），阿利西尤单抗组和依折麦布组患者的总胆固醇、甘油三酯和低密度
脂蛋白胆固醇水平均显著降低（P＜0.05）。随访期间，3组患者的MACE总发生率和头痛、腹痛等其他ADR总发生率比较，差异均
无统计学意义（P＞0.05）。结论 阿利西尤单抗联合阿托伐他汀可显著改善PCI术后ACS患者的心功能，调节其脂代谢指标水平，
且不会增加MACE或其他ADR的发生风险。
关键词 阿利西尤单抗；阿托伐他汀；急性冠脉综合征；经皮冠脉介入术；临床疗效；安全性；心功能；脂代谢；主要心血管不良事件

Effects of alirocumab combined with atorvastatin on clinical efficacy and safety in patients with acute
coronary syndrome after PCI
HAO Cuijun，WANG Rui，MA Yiping，ZHANG Xueping，LIU Yanan，QIN Shaoqiang（Dept. of Cardiology， the
First Affiliated Hospital of Hebei North University， Hebei Zhangjiakou 075000， China）

ABSTRACT OBJECTIVE To investigate the effects of alirocumab combined with atorvastatin on clinical efficacy and safety of
patients with acute coronary syndrome （ACS） who underwent percutaneous coronary intervention （PCI）. METHODS A total of
207 patients with ACS who underwent PCI in our hospital from January 2021 to December 2023 were randomly divided into
alirocumab group， ezetimibe group and control group， with 69 cases in each group. All patients received routine thrombosis
prevention and antihypertensive treatment after PCI. On this basis， patients in the control group were treated with atorvastatin （20
mg/time， once a day）； patients in the ezetimibe group were treated with ezetimibe （10 mg/time， once a day） + atorvastatin （20
mg/time， once a day）； patients in the alirocumab group were treated with alirocumab （75 mg/time， once every 2 weeks） +
atorvastatin （20 mg/time， once a day）. All patients in the three groups were treated for 8 weeks and followed up for another 6
months after treatment. The levels of cardiac function and lipid metabolism indices before and after treatment， as well as the
occurrence of major adverse cardiovascular event （MACE） and other adverse drug reaction （ADR） during the follow-up period
were compared among the three groups. RESULTS After treatment for 8 weeks， the levels of cardiac function and lipid metabolism
indices in the three groups were significantly improved compared with those before treatment （P＜0.05）. Compared with the control
group and ezetimibe group， the left ventricular ejection fraction in the alirocumab group was significantly increased， and the left
ventricular end-diastolic diameter （LVEDD） was significantly shortened （P＜0.05）. Compared with control group， LVEDD of
ezetimibe group was significantly shortened （P＜0.05）， the
Δ 基金项目 河北省自然科学基金项目（No.2022HBKJ00033）；张
levels of total cholesterol， triglyceride and low-density
家口市科技计划自筹经费项目（No.2322147D）
lipoprotein cholesterol in the alirocumab group and ezetimibe
＊第一作者 主治医师，硕士。研究方向：心血管病学。E-mail：
xinneikehcj@163.com group were significantly decreased （P＜0.05）. During the
# 通信作者 副主任医师，硕士。研究方向：心血管病学。E-mail： follow-up period， there was no significant difference in the
xinneikewr@163.com total incidence of MACE and the total incidence of other ADR

· 1216 · China Pharmacy 2025 Vol. 36 No. 10 中国药房 2025年第36卷第10期